Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Shuttle Pharmaceuticals Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Shuttle Pharmaceuticals Holdings's regulatory disclosures and financial reporting.
Shuttle Pharmaceuticals Holdings, Inc. is registering 625,156 shares of common stock for resale by a single selling stockholder. These shares are issuable upon exercise of a pre-funded warrant that was sold in a November 2025 private placement for approximately $2.5 million of gross proceeds already received by the company, so Shuttle will not receive any cash from the resale of these shares.
Shuttle Pharma is a development-stage oncology company focused on radiation-enhancing therapies, led by its Ropidoxuridine program, which has advanced into a Phase II clinical trial in brain cancer patients undergoing radiation therapy after a completed Phase I study. The company highlights substantial risks, including the potential pressure on its share price from resale of these registered shares and other issuances, as well as a going concern uncertainty noted by its independent auditor. Shuttle is also pursuing a contemplated asset acquisition from Molecule, which it cautions may carry integration and execution risks.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports that it was out of compliance with Nasdaq’s stockholders’ equity listing rule after disclosing stockholders’ equity of $1,394,161 in its quarterly report for the period ended September 30, 2025, below the $2,500,000 minimum required for the Nasdaq Capital Market. The company states it now believes it has regained compliance based on a private placement completed on November 4, 2025 that raised approximately $2.5 million in gross proceeds before fees and expenses. Nasdaq staff will continue to monitor equity levels, and if the company does not demonstrate compliance with Listing Rule 5550(b)(1) in its next periodic report, its common stock may be subject to delisting.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported third‑quarter results with no revenue and a net loss of $2.35 million. For the nine months ended September 30, 2025, the company recorded a net loss of $9.11 million. Operating expenses were $2.27 million in the quarter, led by research and development of $0.94 million and general and administrative of $0.89 million.
Cash and cash equivalents were $2.09 million at quarter‑end. Total assets were $3.54 million, liabilities $2.15 million, and stockholders’ equity $1.39 million. The company executed multiple financings in 2025, including $5.0 million net proceeds from a March public offering and $3.9 million net from a June private placement with pre‑funded warrants; a $2.0 million revolving note remained undrawn. On November 3, 2025, SHPH closed a private placement of a pre‑funded warrant for gross $2.5 million. Management disclosed substantial doubt about continuing as a going concern. The company also signed a binding term sheet on October 20, 2025 to acquire Molecule’s assets and liabilities for $10,000,000 in cash and stock, subject to definitive agreements and approvals.
Shuttle Pharmaceuticals Holdings, Inc. entered a securities purchase agreement for a private placement of a pre-funded warrant to purchase up to 625,156 shares of common stock, delivering approximately $2.5 million in gross proceeds. The transaction closed on November 4, 2025.
The warrant is immediately exercisable at $0.001 per share and includes a beneficial ownership cap of 4.99%, adjustable up to 9.99% with 61 days’ prior notice. The company agreed to file a resale registration statement within 15 days of the agreement date and to have it declared effective within 45 days (or 75 days if reviewed by the SEC). For 15 days after closing, the company agreed not to issue or announce new equity or file other registration statements, except as contemplated.
WestPark Capital acted as placement agent and received a cash fee equal to 4% of gross proceeds.
Shuttle Pharmaceuticals Holdings (SHPH) reported an insider ownership update. A director filed an initial Form 3 reflecting beneficial ownership status as of 09/12/2025.
The filing shows 0 shares of common stock held directly and lists no derivative securities. This is an administrative disclosure of insider holdings and does not reflect a transaction.
Shuttle Pharmaceuticals Holdings (SHPH) director filed an initial Form 3 disclosing beneficial ownership as of 09/12/2025. The filing reports 0 shares of common stock beneficially owned and no listed derivative securities. It was filed by one reporting person in the capacity of director, indicating no equity holdings at the time of the event.
Shuttle Pharmaceuticals (SHPH) disclosed two material updates. On October 20, 2025, the company signed a binding term sheet to purchase substantially all assets and liabilities of 1542770 BC Ltd. (Molecule) for $10,000,000, payable over time in a mix of cash and SHPH common stock at the company’s determination and tied to milestones. Closing remains subject to definitive agreements, board approval, and due diligence.
Separately, on October 15, 2025, Theradex Systems, the company’s primary CRO, delivered a notice terminating the 2018 master agreement and demanding immediate payment of $1.091 million. The letter cites a contract provision allowing termination for material breach and states Services will cease if payment is not made within 30 days of the letter. Together, the prospective acquisition outlines a strategic transaction, while the CRO action introduces operational and payment pressure until resolved.
Shuttle Pharmaceuticals Holdings, Inc. entered into a material consulting agreement with IR Agency LLC on September 15, 2025. IR Agency will provide marketing and advertising services to communicate information about the company to the financial community, including creating company profiles, distributing media, and building a digital community around the company.
As consideration for these services, the company paid IR Agency $1,450,000 for a two‑month term. The full consulting agreement is referenced as an exhibit to the report.
Shuttle Pharmaceuticals Holdings, Inc. reported changes to its board leadership. On September 12, 2025, Sachin Pathigoda and Angel Liriano were appointed as directors. On September 15, 2025, Mr. Pathigoda became Chairman of the Nominating and Corporate Governance Committee and joined the Audit Committee, while Mr. Liriano became Chairman of the Compensation Committee and joined the Nominating and Corporate Governance Committee. The company also named existing director George Scorsis as Chairman of the Audit Committee. The filing notes there are no family relationships with current directors or executive officers, no related-party transactions requiring disclosure, and no special arrangements or understandings behind the new director appointments.
Shuttle Pharmaceuticals Holdings, Inc. reported that on September 11, 2025, director Joseph Tung resigned from its board of directors. The company stated that Mr. Tung’s resignation was not the result of any disagreement that would require disclosure under the relevant SEC rules, indicating it was not tied to a reportable dispute over company operations, policies, or practices.